Collaborating to heal addiction and mental health in primary care (CHAMP): A protocol for a hybrid type 2a trial

IF 2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
John C. Fortney , Anna D. Ratzliff , Brittany E. Blanchard , Lori Ferro , Julien Rouvere , Erin Chase , Mark H. Duncan , Joseph O. Merrill , Tracy Simpson , Emily C. Williams , Elizabeth J. Austin , Geoffrey M. Curran , Michael Schoenbaum , Patrick J. Heagerty , Andrew J. Saxon
{"title":"Collaborating to heal addiction and mental health in primary care (CHAMP): A protocol for a hybrid type 2a trial","authors":"John C. Fortney ,&nbsp;Anna D. Ratzliff ,&nbsp;Brittany E. Blanchard ,&nbsp;Lori Ferro ,&nbsp;Julien Rouvere ,&nbsp;Erin Chase ,&nbsp;Mark H. Duncan ,&nbsp;Joseph O. Merrill ,&nbsp;Tracy Simpson ,&nbsp;Emily C. Williams ,&nbsp;Elizabeth J. Austin ,&nbsp;Geoffrey M. Curran ,&nbsp;Michael Schoenbaum ,&nbsp;Patrick J. Heagerty ,&nbsp;Andrew J. Saxon","doi":"10.1016/j.cct.2024.107700","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The gold-standard treatment for opioid use disorder (OUD) is medication for OUD (MOUD). However, less than a quarter of people with OUD initiate MOUD. Expanding the Collaborative Care Model (CoCM) to include primary care patients with OUD could improve access to and initiation of MOUD. This paper presents the methods and baseline sample characteristics of a Hybrid Type 2a trial comparing the effectiveness of CoCM for OUD and co-occurring mental health symptoms (MHS) to CoCM for MHS only.</div></div><div><h3>Method</h3><div>42 primary care clinics were cluster randomized and 254 primary care patients with OUD and elevated MHS were enrolled. Recruitment was terminated early by the Data and Safety Monitoring Board for futility. Participants completed research assessments at baseline, 3 months, and 6 months. The multiple primary outcomes were past-month number of days of nonmedical opioid use and SF12 Mental Health Component Summary (MCS) scores.</div></div><div><h3>Results</h3><div>MCS scores were over a standard deviation below the national mean (M = 34.5). Nearly half (47.6 %) of participants had previously overdosed in their lifetimes. Three quarters (76.0 %) were already being prescribed MOUD at baseline, only 30.4 % reported non-medical use of opioids, and only 33.9 % reported being bothered by opioid cravings.</div></div><div><h3>Conclusion</h3><div>The unexpectedly high proportion of enrollees already prescribed MOUD at baseline indicates that most patients were in the maintenance rather than acute phase of treatment. Challenges identifying and enrolling patients in the acute phase of OUD treatment implies that intervention effectiveness will depend on its success preventing the discontinuation of MOUD rather than initiating MOUD.</div></div>","PeriodicalId":10636,"journal":{"name":"Contemporary clinical trials","volume":"146 ","pages":"Article 107700"},"PeriodicalIF":2.0000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contemporary clinical trials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1551714424002830","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The gold-standard treatment for opioid use disorder (OUD) is medication for OUD (MOUD). However, less than a quarter of people with OUD initiate MOUD. Expanding the Collaborative Care Model (CoCM) to include primary care patients with OUD could improve access to and initiation of MOUD. This paper presents the methods and baseline sample characteristics of a Hybrid Type 2a trial comparing the effectiveness of CoCM for OUD and co-occurring mental health symptoms (MHS) to CoCM for MHS only.

Method

42 primary care clinics were cluster randomized and 254 primary care patients with OUD and elevated MHS were enrolled. Recruitment was terminated early by the Data and Safety Monitoring Board for futility. Participants completed research assessments at baseline, 3 months, and 6 months. The multiple primary outcomes were past-month number of days of nonmedical opioid use and SF12 Mental Health Component Summary (MCS) scores.

Results

MCS scores were over a standard deviation below the national mean (M = 34.5). Nearly half (47.6 %) of participants had previously overdosed in their lifetimes. Three quarters (76.0 %) were already being prescribed MOUD at baseline, only 30.4 % reported non-medical use of opioids, and only 33.9 % reported being bothered by opioid cravings.

Conclusion

The unexpectedly high proportion of enrollees already prescribed MOUD at baseline indicates that most patients were in the maintenance rather than acute phase of treatment. Challenges identifying and enrolling patients in the acute phase of OUD treatment implies that intervention effectiveness will depend on its success preventing the discontinuation of MOUD rather than initiating MOUD.
合作治愈初级保健中的成瘾和心理健康(CHAMP):2a 型混合试验方案。
背景:治疗阿片类药物使用障碍(OUD)的黄金标准是药物治疗 OUD(MOUD)。然而,只有不到四分之一的阿片类药物使用障碍患者开始接受药物治疗。将协作护理模式(CoCM)扩展至阿片类药物使用障碍的初级保健患者,可以改善阿片类药物使用障碍患者获得和开始药物治疗的情况。本文介绍了一项混合型 2a 试验的方法和基线样本特征,该试验比较了 CoCM 对治疗 OUD 和并发精神健康症状 (MHS) 的有效性,以及 CoCM 对仅治疗 MHS 的有效性:对 42 家初级保健诊所进行随机分组,招募了 254 名患有 OUD 和精神健康症状加重的初级保健患者。数据与安全监控委员会以无效为由提前终止了招募。参与者在基线、3 个月和 6 个月时完成了研究评估。多个主要结果是上个月非医疗使用阿片类药物的天数和 SF12 心理健康成分汇总(MCS)得分:MCS 分数比全国平均值(M = 34.5)低一个标准差以上。近一半(47.6%)的参与者在其一生中曾吸毒过量。四分之三(76.0%)的受试者在基线时已被处方鸦片制剂,只有 30.4% 的受试者报告非医疗使用阿片类药物,只有 33.9% 的受试者报告受到阿片类药物渴求的困扰:基线时已服用 MOUD 的患者比例出乎意料地高,这表明大多数患者处于维持治疗阶段,而非急性治疗阶段。在识别和招募处于阿片类药物治疗急性期的患者方面存在挑战,这意味着干预的有效性将取决于能否成功防止患者停用咀嚼片,而不是启动咀嚼片治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.50%
发文量
281
审稿时长
44 days
期刊介绍: Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers and short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信